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Adjuvant therapyAbstract Purpose: Based on recent advances in the management of patients with sentinel
node (SN)epositive melanoma, we aimed to develop prediction models for recurrence, distant
metastasis (DM) and overall mortality (OM).
Methods: The derivation cohort consisted of 1080 patients with SN-positive melanoma from
nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prog-
nostic factors for recurrence, DM and OM were studied with Cox regression analysis. Signif-
icant factors were incorporated in the models. Performance was assessed by discrimination (c-
index) and calibration in cross-validation across centres. The models were externally validated
using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial par-
ticipants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT)
and 232 screened patients. A nomogram was developed for graphical presentation.
Results: The final model for recurrence and the calibrated models for DM and OM included
ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable
calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70,
respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTC-
DeCOG model identified a robust low-risk group, with all identified low-risk patients (approx-
imately 4% of the entire population) having a 5-year recurrence probability of <25% and an
overall 5-year recurrence rate of 13%. A model including information on completion lymph
node dissection (CLND) showed only marginal improvement in model performance.
Conclusions: The EORTC-DeCOG nomogram provides an adequate prognostic tool for pa-
tients with SN-positive melanoma, without the need for CLND. It showed consistent results
across validation. The nomogram could be used for patient counselling and might aid in adju-
vant therapy decision-making.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The American Joint Committee on Cancer (AJCC)
staging system is the most widely accepted approach to
melanoma staging [1,2]. Patients are classified into
distinct stages based on the tumour node
metastasis criteria where nodal status is based on num-
ber of positive lymph nodes after completion lymph
node dissection (CLND) in case of a positive sentinel
node (SN) or after a therapeutic lymph node dissection
in case of clinically apparent nodal disease. Recently
there have been many advances in the care of patients
with SN-positive melanoma that also affect staging,
namely CLND is no longer routine practice as the
Multicenter Selective Lymphadenectomy Trial-II
(MSLT-II) and the German Dermatologic Cooperative
Oncology Group study (DeCOG-SLT) demonstrated no
survival benefit for CLND [3e6] and as immune
checkpoint inhibition and targeted therapy have been
introduced in the adjuvant setting with highly encour-
aging results [7e10]. Consequently the AJCC staging
system is likely to be less appropriate for patients with
SN-positive melanoma not undergoing CLND because
of decreased discriminatory ability [11] as the number of
positive nodes after sentinel lymph node biopsy (SLNB)
is not an independent prognostic factor [3,4] (in contrast
to involved non-SNs retrieved after CLND [3]). As a
result, omitting CLND could result in poorer risk
stratification and impaired selection for adjuvanttherapy. On the other hand, SN tumour burden has
been shown to be an independent predictor of involved
non-SNs [12e14], and therefore SN tumour burden may
serve as a surrogate.
The objective of the present study was to identify
independent prognostic factors in a large European SN-
positive melanoma population, using solely information
from the primary melanoma and the SLNB, to develop
a prediction model for recurrence, distant metastasis
(DM) and overall mortality (OM), presented in the form
of a nomogram. The resulting model could aid in
adjuvant therapy decision-making. The prediction
models were externally validated using a large prospec-
tive German cohort.
2. Patients and methods
2.1. Cohort characteristics
2.1.1. Derivation cohort
The retrospective derivation cohort consisted of 1080
patients with SN-positive melanoma who underwent
SLNB between 1993 and 2008 in one of nine EORTC
Melanoma Group centres that have been previously
collected and described [11,15e17]. The current study
only excluded duplicate cases (nZ 2), leading to a total
of 1078 eligible SN-positive patients. The two duplicate
cases concerned an error in that database. The applied
procedures have been described previously [11].
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The prospective German validation cohort involved two
sets of patients. The first set consisted of 473 patients
who were included in the DeCOG-SLT multicentre
randomised phase-3 trial comparing survival between
patients with SN-positive melanoma who did or did not
undergo CLND [4]. The second set consisted of an
additional 219 patients from a single centre (University
Hospital, Tuebingen) who were initially screened for
inclusion in the DeCOG-SLT trial but were not included
because of meeting the trial’s exclusion criteria (e.g.
head and neck melanoma, age >75 years), unwillingness
to participate, or no known reason. They also did or did
not undergo CLND and were followed and prospec-
tively registered in accordance with similar protocols.
All patients had a tumour thickness of at least 1 mm and
underwent surgery between 2006 and 2014. The study
design, applied procedures and follow-up protocols have
been described in detail elsewhere [4]. There was no
overlap between the derivation cohort and validation
cohort.
2.2. Outcomes
Outcomes of interest were first recurrence, first DM and
OM. Time to recurrence was calculated from date of
SLNB to date of first recurrence or date of death by any
cause. Time to first DM was calculated from date of
SLNB to date of first DM or date of death by any cause.
Time to OM was calculated from date of SLNB to date
of death by any cause.
2.3. Statistical analysis
The checklist proposed by the AJCC was used for
guidance in building a high-quality prediction model
[18]. Associations between possible prognostic factors
and recurrence were studied with Cox regression anal-
ysis. The following eight variables were identified as
possible prognostic factors based on clinical experience,
literature review and availability of sufficient data: sex,
age, ulceration, location, histology, Breslow thickness,
total number of SNs removed and total number of
positive SNs. To make efficient use of available data, an
advanced multiple imputation of missing values strategy
(5 imputations) was applied [19]. This was done sepa-
rately for each derivation centre to avoid using infor-
mation of missings in cross-validation. The possible
non-linearity of continuous variables was modelled by
logarithmic transformation. Independent prognostic
factors were selected with multivariable backwards se-
lection. Linear predictor values (the sum of truncated
predictor values times their predictor effects) were scaled
and rounded to a risk score with integer values between
0 and 100. Because recurrence, DM and OM are
strongly related, the final recurrence prediction model
based on data from all nine EORTC centres was used asa basis for predicting DM and OM, where the baseline
hazard and the slope of the recurrence prediction model
were calibrated to DM and OM [20]. This approach is
beneficial as it provides a unique risk score for each
individual that translates into probabilities of all out-
comes of interest, instead of developing three indepen-
dent prediction models. To test the validity of our
approach, we did develop these independent models and
compared them with the calibrated models. The abso-
lute risk prediction of each outcome was plotted against
the risk score. To reduce overestimation of events
occurring in patients with extremely high scores, scores
were truncated at an integer of 23, corresponding to the
99th percentile of score distribution. Model perfor-
mance was assessed by examining discrimination and
calibration. Discrimination was measured using the
concordance index (c-index); the closer to 1, the better
the discrimination, and a value of 0.5 indicates that the
model is no better than a chance [21]. Calibration was
assessed visually by plotting the predicted probability
against the actual observed frequency in quintiles of
predicted outcomes. A 45 line indicates perfect cali-
bration (when the predictive value of the model perfectly
matches the patient’s actual risk). Any deviation above
or below the 45 line indicates underprediction or
overprediction, respectively. A nomogram was devel-
oped for graphical presentation of the models. To
evaluate generalisability of the models across different
centres, an internaleexternal cross-validation was per-
formed in which the model was fitted using data from
eight centres and validated in the centre that was left out
[22]. In addition we performed external validation using
the prospective German cohort. We first needed to
develop a model for recurrence where we replaced the
continuous variable SN tumour burden with the cate-
gorical substitute used in the prospective German cohort
(single cells, <0.5 mm, 0.5e1.0 mm, >1.0e2.0 mm,
>2.0e5.0 mm and >5.0 mm). For the derivation cohort,
single cells were defined as <0.1 mm according to the
Rotterdam criteria [23]. Single cells in the validation
cohort were not specifically defined, but as the Rotter-
dam criteria were used for measuring SN tumour
burden, definitions are likely to correlate. The perfor-
mance of this altered model was compared with the final
recurrence model used for the nomogram.
Subsequently the altered model was externally validated
with the 692 patients from the prospective German
cohort. To test how much the information on additional
positive nodes retrieved after CLND would add to the
discrimination of the prediction model, we also devel-
oped a prediction model in which the variable, addi-
tional positive nodes after CLND, was added. This
model was based on 1015 patients that underwent
CLND in the derivation cohort.
Furthermore we calculated the model performance
for recurrence, DM and OM of the AJCC 7th edition
classification, AJCC 8th edition classification and the
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absent/present ulceration and low/high SN tumour
burden) was tested [11]. Lastly the observed outcomes
per group for all classifications were estimated using the
Kaplan Meier analysis. All statistical tests were two-
sided, with a P < 0.05 considered statistically signifi-
cant. All statistical analyses were performed using SPSS
version 22.0 (IBM, Armonk, New York, USA) and R
(version 2.15, R Foundation for Statistical Computing,
Vienna, Austria, 2011).Table 1
Baseline characteristics of derivation and validation cohort.
Characteristic Derivation
cohort
Validation
cohort
P valueb
(n Z 1078) (n Z 692)
Age, yearsa n Z 1077 <0.001c
51 (40e62) 57 (46e68)
Gender <0.001
Female 509 (47.2) 267 (38.6)
Male 569 (52.8) 425 (61.4)
Breslow, mma n Z 1076 <0.001c
3.0 (1.9e4.8) 2.4 (1.6e4.0)
Ulceration n Z 1015 n Z 596 0.570
Absent 536 (52.8) 306 (51.3)
Present 479 (47.2) 290 (48.7)
Location <0.001
Extremity 614 (57.0) 335 (47.0)
Trunk 426 (39.5) 355 (51.3)
Head and neck 38 (3.5) 12 (1.7)
Positive SNs n Z 984 n Z 690 <0.001
1 node 775 (78.8) 623 (90.3)
2 nodes 164 (16.7) 60 (8.7)
>2 nodes 45 (4.6) 7 (1.0)
SN tumour burden, mm 0.9 (0.4e2.5) - e
SN tumour burden,
extended
n Z 626 <0.001
Single cellsd 113 (10.5) 187 (29.9)
<0.5 mm 221 (20.5) 57 (9.1)
0.5e1.0 mm 235 (21.8) 208 (33.2)
>1.0e2.0 mm 200 (18.6) 114 (18.2)
>2.0e5.0 mm 195 (18.1) 36 (5.8)
>5.0 mm 114 (10.6) 24 (3.8)
SN tumour burden,
simple
n Z 626 <0.001
 1.0 mm 569 (52.8) 452 (72.2)
> 1.0 mm 509 (47.2) 174 (27.8)
CLND <0.001
No 63 (5.8) 384 (55.5)
Yes 1015 (94.2) 308 (44.5)
Positive non-SNse n Z 1007 n Z 302 0.088
None 804 (79.8) 229 (75.8)
1 node 127 (12.6) 53 (17.5)
>1 node 76 (7.5) 20 (6.6)
CLND, completion lymph node dissection; IQR, interquartile range;
SN, sentinel node. Values in parentheses are percentages unless indi-
cated otherwise.
a Values are median (IQR).
b Chi-square test.
c Except ManneWhitney U test.
d For the derivation cohort, single cells were defined as metastasis
<0.1 mm.
e Information retrieved after CLND.3. Results
The retrospective derivation cohort consisted of 1078
and the prospective validation cohort of 692 patients
with SN-positive. Patients in the validation cohort
had less extensive disease in terms of Breslow thick-
ness, number of positive SNs and tumour burden in
the SN compared with those in the derivation cohort
(Table 1).
In the derivation cohort, recurrence at five-years
occurred in 496 patients (46.0%), DM in 437 patients
(40.5%) and OM in 364 patients (33.8%). Median
follow-up time for all survivors was 106 months (inter-
quartile range [IQR] 61e130 months). In the prospective
validation cohort, recurrence at five-years occurred in
267 patients (38.6%), DM in 223 patients (32.2%) and
OM in 174 patients (25.1%). Median follow-up time for
all survivors was 66 months (IQR: 48e94 months).3.1. Models for recurrence, distant metastasis and overall
mortality
The final multivariable Cox model for recurrence after
backwards selection included four independent prog-
nostic factors: ulceration, age, Breslow thickness and SN
tumour burden (Table 2). Logarithmic transformation
of the continuous variables adequately represented their
effects. The c-index for the final recurrence model was
0.68 (95% confidence interval [CI]: 0.65e0.70). In cross-
validation, the recurrence model was reasonably cali-
brated across nine centres in general, only in smaller
centres there was substantial underestimation of the risk
(Fig. S1).
The association between linear predictors of recur-
rence and DM was of the same size (calibration slope:
1.01, 95% CI: 0.87e1.16). The c-index for the calibrated
model for DM was 0.70 (95% CI: 0.67e0.72) and was
reasonably calibrated across nine centres in cross-
validation (Fig. S2). The performance of this cali-
brated model, based on the baseline hazard and the
slope of the recurrence model, was similar to that of the
independently developed prediction model for DM (c-
index: 0.70, 95% CI: 0.68e0.73).Table 2
Final model for 5-year recurrence (hazard ratio with 95% confidence
interval)a.
Hazard ratio Lower 95 Upper 95
Age 1.28 1.12 1.45
Breslow 1.41 1.23 1.61
SN tumour burden 1.59 1.39 1.81
Ulceration
Absent Reference
Present 1.41 1.16 1.73
SN, sentinel node.
a Includes the final independent prognostic factors selected with
multivariable backwards selection.
Points
0 1 2 3 4 5 6 7 8 9 10
Ulceration
absent
present
Age (years)
25 40 50 75
Tumor burden (mm)
0.05 0.1 0.2 0.4 0.8 1.5 2.5 4 6
Breslow (mm)
0.1 0.15 0.25 0.4 0.6 1 1.5 2.5 4 6 8
Total Points
0 5 10 15 20 25 30
0
25
50
75
0
5
10
15
0 5 10 15 20
Risk score
5−
ye
a
r 
pr
ob
ab
ilit
y 
(%
)
%
 of patients
Death
Distant metastasis
Recurrence
 < 25%
 25−50%
 50−75%
 > 75%
Fig. 1. Nomogram and risk distribution. The curves refer to pre-
dicted recurrence, distant metastasis or overall mortality at 5
years. The histogram refers to the risk score distribution in the
cohort; each bar represents the proportion of patients in the
cohort that was assigned that specific score. The histogram was
divided in four risk groups based on the risk of recurrence: low
risk: <25%, intermediate risk: 25e50%, high risk: 50e75% and
very high risk: >75%. The nomogram incorporates four factors:
ulceration, age, SN tumour burden and Breslow thickness. To
calculate an individual’s probability of 5-year recurrence, distant
metastasis and overall mortality, values for the prognostic factors
must be determined first (for example: absent ulceration, 35 years,
SN tumour burden 0.8 mm and Breslow thickness 1.0 mm). Sec-
ond, for each value the corresponding points can be obtained by
drawing a line from each value towards the point axis (in example:
0, 1, 4 and 5 points, respectively). Third, the points must be added
up to obtain the total risk score (in example: risk score of 10).
Finally, the 5-year recurrence, distant metastasis and overall
mortality probability can be read by moving vertically from the x-
axis (total risk score) to the predicted risk curves and corre-
sponding probabilities on the left y-axis (in example: 26% for
recurrence, 20% for distant metastasis and 16% for overall
D. Verver et al. / European Journal of Cancer 134 (2020) 9e18 13The association between linear predictors of recur-
rence and OM was of the same size (calibration slope:
1.04, 95% CI: 0.88e1.20). The c-index for the calibrated
model for OM was 0.70 (95% CI: 0.67e0.73), and was
reasonably calibrated across nine centres in cross-
validation (Fig. S3). The performance of this cali-
brated model was similar to that of the independently
developed prediction model for OM (c-index: 0.70, 95%
CI: 0.68e0.73).
A four-item risk score was developed, assigning
points to each prognostic factor based on the magnitude
of association with recurrence. A nomogram to calculate
the score and the risk of recurrence, DM and OM is
presented in Fig. 1. The scores were divided into four
risk groups based on the 5-year probability of recur-
rence: <25% (low risk; score 6e9; 4.1% of the popula-
tion); 25e50% (intermediate risk; score 10e15; 52.9% of
the population); 50e75% (high risk; score 16e19; 33.2%
of the population); and >75% (very high risk; score
20e23; 10.0% of the population). The observed out-
comes for recurrence, DM and OM per risk group are
shown in Table 3.
3.2. External validation
For external validation purposes, an altered recurrence
model was developed using the categorised SN tumour
burden variable used in the prospective German cohort
(Table S1). This altered model showed similar perfor-
mance compared with the final recurrence model (c-
index 0.68, 95% CI: 0.65e0.70). In external validation,
the c-index for the altered recurrence model was 0.70
(95% CI: 0.67e0.74), for DM 0.72 (95% CI: 0.68e0.75)
and for OM 0.74 (95% CI: 0.71e0.78). The calibration
plots indicate good calibration, though there may be
slight underestimation for higher-risk patients in the
recurrence and OM models (Fig. S4).
3.3. Additional prognostic value of CLND
An extended model for recurrence was created by add-
ing the variable, number of additional positive nodes
after CLND, to the final recurrence model. This
extended model for recurrence had a c-index of 0.69
(95% CI: 0.67e0.72). The calibrated extended models
for DM and OM showed c-indices of 0.72 (95% CI:
0.69e0.74) and 0.72 (95% CI: 0.69e0.75), respectively.
3.4. Simple classification
A simplified version of the model stratifies patients into
four groups based on ulceration and SN tumour burden:mortality). The percentage of patients in the entire population
(1078) that also had a total risk score of 10 can be determined
from the histogram, as well as the corresponding percentage of
patients on the right y-axis (in example: 7%).
Table 3
Observed outcomes per classification in the derivation cohort.
Risk groups Recurrence Distant metastasis Overall mortality
EORTC-DeCOG model
Low risk (<25% recurrence) 0.13 (0.06e0.20) 0.10 (0.04e0.16) 0.07 (0.02e0.13)
Intermediate risk (25e50% recurrence) 0.38 (0.33e0.43) 0.31 (0.26e0.36) 0.25 (0.21e0.30)
High risk (50e75% recurrence) 0.61 (0.56e0.66) 0.55 (0.49e0.60) 0.49 (0.43e0.54)
Very high risk (>75% recurrence) 0.82 (0.73e0.88) 0.78 (0.69e0.84) 0.70 (0.61e0.77)
Simple classification
Group 1 0.32 (0.26e0.36) 0.26 (0.21e0.30) 0.21 (0.16e0.25)
Group 2 0.52 (0.44e0.58) 0.48 (0.40e0.54) 041 (0.33e0.47)
Group 3 0.49 (0.41e0.55) 0.42 (0.34e0.48) 0.35 (0.28e0.42)
Group 4 0.73 (0.67e0.77) 0.69 (0.63e0.74) 0.60 (0.53e0.66)
AJCC 7th edition
IIIA  1.0 mm 0.32 (0.26e0.37) 0.25 (0.20e0.30) 0.20 (0.15e0.25)
IIIA >1.0 mm 0.50 (0.42e0.57) 0.46 (0.38e0.53) 0.40 (0.32e0.46)
IIIB 0.63 (0.58e0.67) 0.57 (0.52e0.62) 0.49 (0.44e0.53)
IIIC 0.60 (0.02e0.84) 0.62 (0.02e0.85) 0.63 (0.02e0.86)
AJCC 8th edition
IIIA  1.0 mm 0.27 (0.20e0.34) 0.21 (0.15e0.28) 0.15 (0.09e0.21)
IIIA >1.0 mm 0.37 (0.23e0.49) 0.34 (0.20e0.46) 0.27 (0.14e0.38)
IIIB 0.43 (0.36e0.48) 0.35 (0.29e0.41) 0.30 (0.24e0.36)
IIIC 0.64 (0.59e0.68) 0.48 (0.53e0.63) 0.50 (0.45e0.55)
IIID 0.66 (0.00e0.90) 0.68 (0.00e0.91) 0.70 (0.00e0.92)
AJCC, American Joint Committee on Cancer; CI, confidence interval. Values in parentheses are 95% confidence intervals. This table provides
observed outcomes for 5-year recurrence, distant metastasis and overall mortality per risk group, e.g. when classified as low risk according to the
EORTC-DeCOG model the observed 5-year recurrence was 0.13 with a 95% confidence interval of 0.06e0.20.
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and >1.0 mm; 3) present ulceration and 1.0 mm and 4)
present ulceration and >1.0 mm11. The c-indices for this
classification in predicting recurrence, DM and OM
were 0.63 (95% CI: 0.61e0.65), 0.64 (95% CI:
0.62e0.67) and 0.64 (95% CI: 0.61e0.67), respectively.
The observed outcomes for recurrence, DM and OM per
risk group are shown in Table 3.
3.5. The American Joint Committee on Cancer (AJCC)
classifications
Patients were classified based on the 7th AJCC classifi-
cation into IIIA  1.0 mm, IIIA >1.0 mm, IIIB andTable 4
Cross-table comparing EORTC-DeCOG risk groups with the 7th and 8th
EORTC-DeCOG classification AJCC 7th classification
IIIA 1.0 mm IIIA >
Low risk (score 6e9) 82 2
Intermediate risk (score 10e15) 207 83
High risk (score 16e19) 15 89
Very high risk (score 20e23) 0 11
Total 304 185
EORTC-DeCOG classification AJCC 8th classification
IIIA 1.0 mm IIIA >
Low risk (score 6e9) 62 3
Intermediate risk (score 10e15) 96 43
High risk (score 16e19) 0 10
Very high risk (score 20e23) 0 0
Total 158 56
AJCC, American Joint Committee on Cancer.IIIC and based on the 8th edition into IIIA  1.0 mm,
IIIA >1.0 mm, IIIB, IIIC and IIID. The c-indices for
predicting recurrence, DM and OM for the 7th AJCC
edition were 0.61 (95% CI: 0.59e0.63), 0.62 (95% CI:
0.60e0.65) and 0.62 (95% CI: 0.59e0.65), respectively,
and for the 8th AJCC edition 0.62 (95% CI: 0.59e0.64),
0.63 (95% CI: 0.60e0.65) and 0.63 (95% CI: 0.61e0.66),
respectively. The observed outcomes for recurrence, DM
and OM for both AJCC classifications are shown in
Table 3. A cross-table comparing the patients staged in
accordance with the AJCC classifications and the risk
groups based on the EORTC-DeCOG model is illus-
trated in Table 4. An overview of c-indices for all the
different models is presented in Table 5.AJCC classification, based on 937 complete cases.
1.0 mm IIIB IIIC Total
5 0 89
93 2 385
230 1 335
113 4 128
441 7 937
1.0 mm IIIB IIIC IIID Total
22 2 0 89
157 89 0 385
71 253 1 335
2 122 4 128
252 466 5 937
Table 5
C-indices with 95% confidence intervals for the different prediction models.
Recurrence Distant metastasisa Overall mortalitya
EORTC-DeCOG prediction model 0.68 (0.65e0.70) 0.70 (0.67e0.72) 0.70 (0.67e0.73)
EORTC-DeCOG altered model
Derivation cohort 0.68 (0.65e0.70) 0.70 (0.67e0.72) 0.70 (0.67e0.73)
External validation 0.70 (0.67e0.74) 0.72 (0.68e0.75) 0.74 (0.71e0.78)
EORTC-DeCOG extended model 0.69 (0.67e0.72) 0.72 (0.69e0.74) 0.72 (0.69e0.75)
EORTC-DeCOG simple classification 0.63 (0.61e0.65) 0.64 (0.62e0.67) 0.64 (0.61e0.67)
AJCC 7th editionb 0.61 (0.59e0.63) 0.62 (0.60e0.65) 0.62 (0.59e0.65)
AJCC 8th editionc 0.62 (0.59e0.64) 0.63 (0.60e0.65) 0.63 (0.61e0.66)
a Calibrated models.
b For IIIA 1.0 mm, IIIA >1.0 mm, IIIB, IIIC.
c For IIIA 1.0 mm, IIIA >1.0 mm, IIIB, IIIC, IIID. AJCC, American Joint Committee on Cancer; SN, sentinel node.
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The present study developed and validated a nomogram
to predict five-year recurrence, DM and OM in patients
with SN-positive melanoma, by solely using information
from the primary melanoma and SLNB. The resulting
patient-specific probabilities could be used to tailor
adjuvant therapeutic strategies for patients with SN-
positive melanoma, without the prerequisite to undergo
CLND and thereby avoiding potential significant
morbidity. The greatest contemporary value of our
prognostic nomogram is the possibility of identifying
patients at sufficiently low risk for recurrence, DM and
OM in whom adjuvant therapy could be omitted.
Although the FDA and EMA pragmatically
approved adjuvant therapy for all stage-III patients, it is
still under debate which patients should not be consid-
ered candidates. Patients with stage IIIA 1.0 mm
(AJCC 7th edition) were considered low risk in most
adjuvant therapy trials and were therefore not included
(one even excluded all IIIA patients) [7e9,24,25]. The
current study indicates that when the AJCC 8th edition
criteria are used for defining IIIA 1.0 mm instead of
the 7th edition, it results in improved selection of low-
risk patients in terms of predicted prognosis (e.g. 5-year
recurrence probability of 27% versus 32%, respectively).
A recent study also showed that including SN tumour
burden to the 8th AJCC staging system has crucial
prognostic relevance [26]. Of note our EORTC-DeCOG
model is able to identify an even more robust low-risk
group, as all identified low-risk patients (which
approximately concerned 4% of the entire population
after imputation) had a 5-year recurrence probability of
<25% and an overall 5-year observed recurrence rate of
13%. However, identifying more robust low-risk groups
comes at the cost of fewer patients being assigned low
risk (see Table 4). Nonetheless a major advantage of our
EORTC-DeCOG model is that it provides a more
continuous type of predicted probabilities. As a result it
is possible to derive risk groups based on outcome
probabilities and/or risk scores (e.g. low risk; scores6e9; recurrence probability of <25%) which is in
contrast to the AJCC classifications where exact patient/
tumour characteristics define the risk groups (e.g. IIIA
1.0 mm: T1a/b-T2a þ N1a-N2a with 1.0 mm SN
tumour burden). In the current study we choose to
derive risk groups based on the recurrence probability,
as this seems the most relevant outcome in the context of
selecting patients for adjuvant therapy; other cut-off
values and/or outcomes are possible. In conclusion,
the EORTC-DeCOG model not only outperforms the
AJCC classifications in terms of overall model discrim-
ination (see Table 5), but also seems to be able to
identify a more robust low-risk group in whom it may be
justified to forego adjuvant therapy.
The previously published simplified model, based on
ulceration and SN tumour burden, harboured the least
performance, though still reasonable, and showed
similar predicted prognosis for the low-risk group as the
7th AJCC edition. Whether to implement a more com-
plex model versus a less robust model is a balance be-
tween performance and simplicity. In our opinion, the
simple model could serve as an easy user-friendly
prognostic tool for daily clinical practice and to gener-
ally inform patients, but for more adequate risk esti-
mates and decisions upon (adjuvant) treatment, we
advocate using the comprehensive EORTC-DeCOG
model. Noteworthy, besides the common prognostic
factors (i.e. ulceration, Breslow thickness and SN
tumour burden), the current study also identified
increasing age as an independent prognostic factor for
recurrence, DM and OM. This finding is supported by
other studies reporting on the significance of the
patient’s age [27].
Stratifying for ulceration and SN tumour burden
only was previously demonstrated to yield similar
discriminatory ability for melanoma-specific mortality
as stratifying for AJCC substages which included in-
formation on nodal status after CLND [11]. The addi-
tional value of non-SN status retrieved after CLND was
also tested in the current study, by developing an
extended model. This model showed only marginal
D. Verver et al. / European Journal of Cancer 134 (2020) 9e1816improvement in performance (e.g. c-index for the
recurrence model increased from 0.68 to 0.69), thereby
indicating that omitting CLND has very limited conse-
quences for prognostication if SN tumour burden is
taken into account.
This study has several limitations. First is the retro-
spective design of the derivation cohort, which has
inherent biases. However, the models proved to be
successful in external validation. Performance was
comparable between the derivation and prospective
validation cohort, even though the latter cohort
included patients with relatively better prognosis (e.g.
less extensive disease) and largely represents a clinical
trial population. Adjuvant interferon-ɑ therapy was
intended in approximately 60% of the patients included
in the DeCOG-SLT trial, which is another possible
limitation [4]. It could have potentially influenced out-
comes, especially in patients with ulcerated melanomas
as ulceration seems to be a predictive factor for IFN
sensitivity [28,29]. Furthermore, it is unknown how
many patients in the validation cohort received effective
novel therapy after recurrence. Because patients were
included from 2006 through 2014, it is likely some pa-
tients did. As patients in the derivation cohort were
included from 1993 through 2008, novel therapies
probably had limited effect. To date, no novel
biomarker has been validated that suffices to predict
long-term clinical benefits and subsequently could be
incorporated in the models, despite efforts in this di-
rection (e.g. PD-L1) [30]. In addition, other prognostic
factors such as mitotic rate or microsatellites could not
be incorporated in the present models because of
insufficient data. Another limitation is the inadequate
representation of patients with SN-positive with a head
and neck melanoma in both cohorts. For the validation
cohort this is largely explained as it was an exclusion
criterion in the DeCOG-SLT trial, and for the deriva-
tion cohort this might be partially explained by the
historical concerns of poor safety, accuracy and prog-
nostication. Similar numbers (~5%) have been reported
in other European cohorts [31,32], while particularly
American cohorts have reported higher numbers
(>10%) [3,33]. With the introduction of adjuvant ther-
apies, the number of performed SLNBs in head and
neck melanomas is likely to increase.
Considering the advances in the management of
patients with SN-positive melanoma, it becomes highly
relevant to have a prediction model that provides pre-
cise patient-specific probabilities based on solely fac-
tors from the primary melanoma and the SLNB. The
EORTC-DeCOG nomogram is the first that meets
these demands, and as a result it could be used for
patient counselling and assist in trial design. In
addition it might aid in adjuvant therapy decision-
making. To facilitate its use, an online calculator has
been developed and can be accessed at https://www.
evidencio.com/models/show/2010.Funding
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